Preliminary communication

Early improvement with lithium in classic mania and its association with later response

Rodrigo Machado-Vieiraa,b,*, David A. Luckenbaugha, Marcio G. Soeiro-de-Souzab, Getulio Marcad, Ioline D. Hentera, Joao V. Busnelloc, Wagner F. Gattazb, Carlos A. Zarate Jrade

a Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, NIH, Bethesda, MD, USA
b Laboratory of Neuroscience, LIM-27, Institute and Department of Psychiatry, University of Sao Paulo, SP, Brazil
c Department of Psychiatry and Behavioral Neuroscience, University of Chicago, IL, USA
d Espirita Hospital of Porto Alegre, Porto Alegre, Brazil

ARTICLE INFO

Article history: Received 26 April 2012 Accepted 5 May 2012 Available online 17 August 2012

Keywords: Lithium Mania Bipolar disorder Early response Treatment Mood stabilizer

ABSTRACT

Objectives: Despite lithium’s clinical efficacy in treating mania in bipolar disorder (BD), studies evaluating early improvement and subsequent treatment response are sparse. This study investigated whether early improvement (within one week) to lithium monotherapy predicted later response and remission in individuals with BD mania.

Methods: BD-I patients (n = 46) experiencing a manic episode received lithium monotherapy for four weeks (initial dose: 600 mg/d, adjusted to therapeutic levels); individuals experiencing a mixed episode, rapid cyclers, previous non-responders to lithium, and those with current drug abuse/dependence were excluded. Symptoms were rated using the Young Mania Rating Scale (YMRS) at baseline and at Days 7, 14, 21, and 28.

Results: Thirty-three percent of the total sample responded to lithium within the first week of treatment, defined as a $\geq 50\%$ decrease from baseline YMRS scores; 63% responded by study endpoint. In addition, 39% of the total sample showed early improvement (at least 20% decrease in YMRS scores) after one week of treatment. In this group, 79% responded to lithium by study endpoint. Among those showing less than 20% improvement at Week 1, only 23% responded to lithium by study endpoint.

Limitations: History of episodes sequence was not assessed.

Conclusions: Early improvement in response to lithium monotherapy in subjects with BD mania predicted later response and remission. Most patients who did not show early improvement in response to lithium during the first week of treatment showed no response after one month. The findings provide a valuable clinical tool for early identification of those patients most likely to benefit from lithium in clinical practice.

© 2012 Elsevier B.V. All rights reserved.

Introduction

In the treatment of bipolar disorder (BD), lithium continues to be the gold standard (American Psychiatric Association, 2002; Suppes et al., 2005; Yatham et al., 2009). It has a long history of safe and effective clinical use in the treatment of both the acute manic phase of the illness as well as maintenance therapy for BD. Clinical evidence regarding predictors of initial treatment response—as opposed to maintenance treatment with lithium—is relatively sparse (Goodnick, 1996); indeed, most of the factors that have been described are associated with non-response to lithium. It is beyond the scope of this paper to review these disparate predictors of response and non-response; the interested reader is referred to recent reviews on the subject (Grof, 2010; Kessing et al., 2011).

Briefly, lithium appears to be the mood stabilizer of choice in individuals whose illness is categorized as “classic” mania encompassing euphoric mood (Grof, 2010), in those with a family history of BD (Coryell et al., 2000), and in patients with little psychiatric comorbidity. In contrast, lithium appears to be relatively ineffective in certain subtypes of BD such as mixed states (Dilsaver et al., 1993; McElroy et al., 1992) or dysphoric mania, rapid-cycling, a high prevalence of depressive symptomatology (Cohen et al., 1989; Swann et al., 1997), and mania secondary to organic illness (Himmelhoch and Garfinkel, 1986; Keller et al., 1986; Secunda et al., 1985). In addition, patients with a history of substance abuse are less likely to respond to lithium (Goldberg et al., 1999; Maj, 2003).
Considerable research has been conducted in recent years exploring predictors of treatment response in major depressive disorder (MDD). Studies exploring early improvement (defined as less than two weeks of treatment) as predictors of long-term response and remission to a variety of antidepressants are serving to reshape thinking in psychiatry regarding the speed with which antidepressant response manifests (Nagayama et al., 1991; Katz et al., 1996; Stassen et al., 1996, 1999; Szegedi et al., 2009, Tohen et al., 2010). Notably, those studies support the notion that, for some patients with MDD, early onset of improvement in depressive symptoms may correlate with better short- and long-term outcome. From a public health perspective, such research is particularly important because the ability to rapidly identify individuals who are not likely to respond to initial drug treatment would reduce patient exposure to ineffective medications, thereby allowing the early switch to other, potentially more effective agents (Kemp et al., 2011a,b), and reducing treatment costs (Szegedi et al., 2009).

With regard to BD, few data exist regarding how early improvement in response to lithium influences subsequent response and remission. Here, we report findings from a post-hoc analysis of data from the lithium/placebo arm of a randomized, double-blind, placebo-controlled trial in BD-I (current manic episode) (Machado-Vieira et al., 2008). The aim of this analysis was to determine whether early response (less than one week) to lithium in patients with BD mania predicted later response and remission.

Patients and methods

Sample
Subjects (n = 46; 29F/17M; 18 to 65 years old) had a diagnosis of BD-I and were currently experiencing a manic episode with or without psychotic features, as assessed by the Structured Clinical Interview for Axis I DSM-IV-TR Disorders, Research Version, Patient Version (First et al., 1996). All subjects were evaluated between September 2003 and September 2006 at the Bipolar Disorder Research Center—Espirita Hospital of Porto Alegre. Subjects were required to have a baseline score ≥ 22 on the Young Mania Rating Scale (YMRS) (Young et al., 1978). All subjects were in good physical health as determined by medical history, physical examination, and laboratory test results. Patients had been medication-free for at least four weeks before admission. Exclusion criteria included rapid cycling, mixed episodes, previous history of refractoriness to lithium, current comorbid substance abuse or dependence, and current Axis I psychiatric disorder other than BD. The local institutional review board approved the study. All subjects provided written informed consent.

Study design
Before receiving four weeks of lithium monotherapy for acute mania, patients underwent a two- to seven-day screening period. All patients were started on lithium 600 mg/d; after one week, the dose was increased to 900 mg/d. Thereafter, a flexible dose was used in response to plasma lithium levels (maintained at 0.6–1.2 mmol/L). Concomitant use of diazepam (maximum 20 mg/d) for severe agitation was allowed during the four-week study except for a twelve hour period before rating scales were administered. No antipsychotics were allowed during the study.

Efficacy measures
Subjects were rated at baseline and at Days 7, 14, 21, and 28. The YMRS was the primary outcome measure, and the secondary outcome measure was the Clinical Global Impressions-Severity of Illness (CGI-S) scale. The primary efficacy variable was reduction in YMRS total score from baseline to study endpoint (Day 28). Raters were psychiatrists who displayed an inter-rater reliability of 0.90 for the YMRS.

Three measures of response to lithium were defined. (1) Early improvement: improvement of at least 20% from baseline YMRS score after one week of treatment; (2) Response: 50% improvement from baseline at any time point; and (3) Remission, which was defined as two ways: YMRS score ≤ 12 for the liberal definition, and ≤ 7 for the more stringent definition.

Statistics
Pearson correlations were used to examine the relationship between potential predictors and outcomes on a continuous scale, and chi-square tests were used for categorical measures. The primary analysis was the association between early response and response at study endpoint. Categorical response relationships were examined to give a more clinical view of this relationship. No multiple comparisons correction was applied to these tests. However, Bonferroni correction was used for additional predictors. All tests were evaluated for significance at p < .05, two-tailed.

Results

Prevalence of improvement

Thirty-three percent of patients (15/46) responded to lithium—that is, they had an at least 50% improvement from YMRS baseline score—within the first week of treatment. Another 39% (18/46) showed early improvement, as assessed by an at least 20% reduction in YMRS scores in the first week. With regard to remission, 22% (10/46) of the patients met the more liberally defined remission criteria by the end of Week 1, and 8% (4/46) achieved remission when the stricter remission criteria were used. The average proportion of improvement from baseline was 37% (SD = 25.3).

By study endpoint, 63% (29/46) of the sample had a response to lithium of at least 50%, and another 17% (8/46) improved at least 20% compared to baseline. Furthermore, 52% (25/46) of the patients met the more liberally defined remission criteria by study endpoint, and 39% (18/46) achieved remission when the stricter remission criteria were used. The average proportion of improvement from baseline was 57.4% (SD = 36.4).

Relationship between early response and endpoint response

A Pearson correlation between the proportion of change at Week 1 and at endpoint was significant (r = .32, p = .03). This suggests a moderate positive relationship between early improvement and later response.

Chi-square tests were used to further examine whether a minimum 20% improvement after one week was related to response or remission at study endpoint. Using 50% improvement at endpoint (response criteria) as the outcome, it was found a significant relationship between early and later outcome (χ² = 12.42, p = .0004; OR = 12.38, sensitivity = .89, specificity = .59, positive predictive value = .79, negative predictive value = .77). Of those patients showing early improvement at Week 1, 79% (26/33) had a 50% or better response by study endpoint. In contrast, for those who had not improved by the end of Week 1, only 23% (3/13) had a response at study endpoint. Similar results were obtained when remission at study endpoint was used as the criterion, regardless of whether the liberal (χ² = 11.09, p = .0009; OR = 12.65) or stricter definition (χ² = 7.52, p = .006; OR = 12.75) was applied. These results are consistent with the previous correlation indicating that early improvement is positively associated with later response.
Predictors of early improvement

Several potential predictors of early response (by Week 1) to lithium were examined. These included baseline YMRS, individual YMRS items, sex, age, age at first episode, duration of illness, psychosis, number of previous psychiatric hospitalizations, number of suicide attempts, number of mood and manic episodes, serum lithium levels, and serum uric acid levels. No significant predictors were identified after correcting for multiple comparisons.

Predictors of endpoint response

Pearson correlations were used to examine the same variables as potential predictors of endpoint response. Again, no significant predictors were identified after correcting for multiple comparisons.

Because sex ($r = -0.30$, $p = 0.045$) was significantly correlated with response before Bonferroni correction, we performed a hierarchical linear regression to determine whether early improvement and sex independently predicted later response, and whether sex added variance to a predictive model that used only early improvement. Early improvement was entered into the model first, and sex was added in a second block. We found that early improvement explained $10\%$ of the variance in later response when included in the model by itself ($p = 0.03$). Early improvement remained a significant predictor after adding sex ($p = 0.04$). Though adding sex increased the amount of variance explained by $7\%$, it was not a significant independent predictor ($p = 0.07$).

Discussion

This study examined a group of BD-I patients with classic euphoric mania receiving lithium monotherapy and found that early improvement predicted subsequent response and remission to lithium at four weeks. In contrast, among those subjects who showed no early improvement during the first week of lithium treatment, less than one-fourth responded to lithium after four weeks.

Recent research has explored predictors of treatment response in patients with MDD receiving antidepressants. Several studies in MDD suggest that improvement within the first two weeks is associated with endpoint treatment response (Nagayama et al., 1991; Katz et al., 1996; Stassen et al., 1993, 1996, 1999; Szegedi et al., 2009; Tohen et al., 2010; Nierenberg et al., 1995). In contrast, and despite its long history of safe clinical use in BD, little clinical evidence exists regarding predictors of initial treatment response—such as the response to lithium (Goodnick, 1996). Fig. 1 Table 1.

Recent work in this area has highlighted agents other than lithium in BD. (Kemp et al., 2011a,b) pooled data from 10 placebo-controlled trials evaluating four different agents—but not lithium—in the treatment of bipolar depression. That study, which considered early improvement as a reduction of $20\%$ or higher from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) scores, reported that the predictive value of early improvement appeared to be both less consistent and less robust in individuals with bipolar depression than in those with MDD; however, the authors did conclude that the absence of early improvement was a reliable predictor of subsequent non-response (Kemp et al., 2011a,b). A similar study exploring early response in BD mania found that patients who responded to olanzapine and risperidone ($\geq 50\%$ reduction on the YMRS) at Week 1 were likely to remain responders at study endpoint (23). In BD patients with acute manic/mixed episodes who received the antipsychotic ziprasidone, early improvement of psychotic symptoms predicted remission at three weeks (Ketter et al., 2010). Another study of BD subjects experiencing a mixed episode who received olanzapine combined with divalproex reported that improvement on CGI-S measures as early as Day 2 predicted remission at six weeks (Houston et al., 2011) Fig. 2.

The present findings could provide information on clinical therapeutics, potentially gaining better understanding from early predictors of subsequent manic episode clinical improvement. However, this study has limitations. First, extrapolation of the relationship between early symptom improvement or persistence and subsequent clinical improvement may not necessarily apply to clinical populations that are not under the controlled conditions.

Table 1

<table>
<thead>
<tr>
<th>Predictor</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (female)</td>
<td>29</td>
<td>63</td>
</tr>
<tr>
<td>Family history of mood disorder (1st degree relatives)</td>
<td>24</td>
<td>52</td>
</tr>
<tr>
<td>Psychosis</td>
<td>21</td>
<td>46</td>
</tr>
<tr>
<td>Study completion</td>
<td>31</td>
<td>67</td>
</tr>
<tr>
<td>Response (end)</td>
<td>29</td>
<td>63</td>
</tr>
<tr>
<td>Remission (end)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>YMRS $&lt;$ 12</td>
<td>25</td>
<td>54</td>
</tr>
<tr>
<td>YMRS $&lt;$ 7</td>
<td>18</td>
<td>39</td>
</tr>
<tr>
<td>Mean Age</td>
<td>29.3</td>
<td>8.5</td>
</tr>
<tr>
<td>Duration of illness (years)</td>
<td>7.9</td>
<td>7.5</td>
</tr>
<tr>
<td>All mood episodes</td>
<td>4.7</td>
<td>3.3</td>
</tr>
<tr>
<td>Previous manic episodes (lifetime)</td>
<td>3.1</td>
<td>2.5</td>
</tr>
<tr>
<td>Hospitalizations</td>
<td>3.1</td>
<td>2.9</td>
</tr>
<tr>
<td>Clinical ratings (baseline)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>YMRS</td>
<td>33.8</td>
<td>1.4</td>
</tr>
<tr>
<td>CGI</td>
<td>5.1</td>
<td>0.2</td>
</tr>
<tr>
<td>Lithium (serum)</td>
<td>0.95</td>
<td>0.20</td>
</tr>
</tbody>
</table>

Fig. 1. Association between early improvement in manic symptoms (decrease $\geq 20\%$ in total YMRS scores after one week of treatment) and response at endpoint (decrease $\geq 50\%$, 28 day).
Lithium continues to be the proof of concept agent and widely used worldwide in the treatment of BD. Over the past decade, treatment guidelines for BD have become routinely available. Such guidelines are particularly useful in BD, given the symptomatic and functional complexity of the illness and its chronic course. Here, early improvement in response to lithium monotherapy is examined including baseline YMRS, individual YMRS items, sex, age, age at first episode, duration of illness, psychosis, number of previous psychiatric hospitalizations, number of suicide attempts, number of mood and manic episodes, serum lithium levels, and serum uric acid levels—no significant predictors could be identified.

Lithium continues to be the proof of concept agent and widely used worldwide in the treatment of BD. Over the past decade, treatment guidelines for BD have become routinely available. Such guidelines are particularly useful in BD, given the symptomatic and functional complexity of the illness and its chronic course. Here, early improvement in response to lithium monotherapy is examined including baseline YMRS, individual YMRS items, sex, age, age at first episode, duration of illness, psychosis, number of previous psychiatric hospitalizations, number of suicide attempts, number of mood and manic episodes, serum lithium levels, and serum uric acid levels—no significant predictors could be identified.

**References**


